Zomedica, Celsee Inc. partner to deliver cancer liquid biopsy platformDecember 21, 2017Zomedica Pharmaceuticals Corp. has entered into a license and supply agreement with Celsee Inc., an innovator of progressive rare cell capture, characterization, and retrieval products in the emerging field of liquid biopsy. Under the terms of the agreement, Zomedica will have animal health exclusive global rights to develop and market Celsee's liquid biopsy platform for use by veterinarians as a cancer diagnostic. A liquid biopsy is a blood test with the potential to detect the presence of circulating tumor cells in the blood. Circulating tumor cells (CTC) are shed from a primary tumor into neighboring blood vessels and are transported throughout the body's circulatory system. The detection of CTCs in the blood could indicate a cancer diagnosis without the need for an invasive tissue biopsy, according to Zomedica. "Liquid biopsy is cutting-edge technology in human medicine right now and we're excited about the opportunity to develop and market this platform for use in veterinary medicine," stated Gerald Solensky, Jr., CEO at Zomedica. "We selected the Celsee platform because of the ease of use, workflow simplicity, and flexibility to use our novel canine biomarkers. If we successfully develop Celsee's technology, we believe we will be able to …
Education Center - SponsoredVector-Borne Disease Coming to a Neighborhood Near You: Which Tests to Reach For, and Why?by • AntechWhether it’s a screening to identify exposure to tick-borne pathogens, or a broad molecular diagnostic panel to help with acute disease detection or confirm the presence of genetic material, these options empower veterinary teams, guide treatment, and support antimicrobial stewardship.
